Navistar International (NAV) Reaches $39.04 After 8.00% Down Move; AGILE THERAPEUTICS (AGRX)’s Sentiment Is 1.12

June 13, 2018 - By Michael Collier

Navistar International Corporation (NYSE:NAV) Logo

The stock of Navistar International Corporation (NYSE:NAV) is a huge mover today! The stock decreased 1.93% or $0.77 during the last trading session, reaching $39.04. About 174,406 shares traded. Navistar International Corporation (NYSE:NAV) has risen 44.77% since June 13, 2017 and is uptrending. It has outperformed by 32.20% the S&P500. Some Historical NAV News: ; 18/04/2018 – International Truck And IC Bus Showcase Advanced Technologies At Green Transportation Summit & Expo; 07/03/2018 – International Truck Unveils The International® MV™ Series; 03/04/2018 – Navistar Names Friedrich W. Baumann Senior Vice Pres of Strategy and Planning; 08/03/2018 – Navistar Sees FY18 Rev $9.25B-$9.75B; 16/04/2018 – Navistar Closes Above 200-Day Moving Average: Technicals; 22/03/2018 – Six Companies Join the Auto-ISAC: Allison Transmission, Autoliv, Calsonic Kansei, Hitachi, Intel and Navistar; 18/04/2018 – NAVISTAR DROPS AS VW SAYS ‘NOT REPORTING ANY CHANGES’ TO PLANS; 16/04/2018 – VW VOWG_p.DE TRUCKS CHIEF LEAVES OPEN WHETHER 16.9 PCT STAKE IN NAVISTAR WILL BE RAISED, TAKEOVER BID NEEDED IF EXCEEDS 17 PCT; 18/04/2018 – Volkswagen Truck & Bus Not Reporting Any Changes to Plans or Proposals for Navistar; 16/04/2018 – VW trucks division open to taking over Navistar -CFOThe move comes after 7 months negative chart setup for the $3.86B company. It was reported on Jun, 13 by Barchart.com. We have $35.92 PT which if reached, will make NYSE:NAV worth $308.48M less.

AGILE THERAPEUTICS INC (AGRX) investors sentiment decreased to 1.12 in 2018 Q1. It’s down -0.59, from 1.71 in 2017Q4. The ratio dived, as 19 active investment managers started new or increased positions, while 17 trimmed and sold positions in AGILE THERAPEUTICS INC. The active investment managers in our database now have: 23.01 million shares, up from 22.48 million shares in 2017Q4. Also, the number of active investment managers holding AGILE THERAPEUTICS INC in top ten positions was flat from 4 to 4 for the same number . Sold All: 4 Reduced: 13 Increased: 14 New Position: 5.

Investors sentiment is 3 in 2018 Q1. Its the same as in 2017Q4. It is the same, as 1 investors sold Navistar International Corporation shares while 0 reduced holdings. only 1 funds opened positions while 2 raised stakes. 383,011 shares or 58.21% more from 242,095 shares in 2017Q4 were reported. Horizon Kinetics Limited Liability Company has 12,088 shares for 0.01% of their portfolio. Westpac Bk holds 0% of its portfolio in Navistar International Corporation (NYSE:NAV) for 152,049 shares. Gotham Asset Mngmt Ltd reported 218,874 shares.

More notable recent Navistar International Corporation (NYSE:NAV) news were published by: Seekingalpha.com which released: “I Am Buying Navistar” on June 13, 2018, also Benzinga.com with their article: “Navistar International Earnings Preview” published on June 04, 2018, Livetradingnews.com published: “Navistar International Corporation (NYSE:NAV) Entry at $35.00” on June 06, 2018. More interesting news about Navistar International Corporation (NYSE:NAV) were released by: Seekingalpha.com and their article: “Navistar higher post Q2 results” published on June 05, 2018 as well as Benzinga.com‘s news article titled: “Longbow Turns Bullish On Commercial Trucking, Upgrades Navistar, Rush Enterprises” with publication date: June 02, 2018.

Among 22 analysts covering Navistar International Corporation (NYSE:NAV), 9 have Buy rating, 2 Sell and 11 Hold. Therefore 41% are positive. Navistar International Corporation had 84 analyst reports since July 27, 2015 according to SRatingsIntel. As per Thursday, September 3, the company rating was maintained by Robert W. Baird. JP Morgan maintained the shares of NAV in report on Tuesday, April 10 with “Neutral” rating. Global Hunter Securities downgraded the stock to “Neutral” rating in Monday, September 28 report. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, March 8. RBC Capital Markets maintained Navistar International Corporation (NYSE:NAV) rating on Monday, July 10. RBC Capital Markets has “Hold” rating and $3100 target. Robert W. Baird maintained Navistar International Corporation (NYSE:NAV) rating on Friday, November 10. Robert W. Baird has “Buy” rating and $53.0 target. The rating was maintained by UBS on Friday, September 16 with “Neutral”. The firm has “Neutral” rating by Seaport Global given on Thursday, April 6. The firm has “Sector Perform” rating given on Friday, December 18 by RBC Capital Markets. The firm has “Underweight” rating given on Wednesday, September 2 by JP Morgan.

Navistar International Corporation manufactures and sells commercial and military trucks, diesel engines, school and commercial buses, and service parts for trucks and diesel engines worldwide. The company has market cap of $3.86 billion. The firm operates through four divisions: Truck, Parts, Global Operations, and Financial Services. It has a 25.12 P/E ratio. It makes and distributes Class 4 through 8 trucks and buses in the common carrier, private carrier, government, leasing, construction, energy/petroleum, military vehicle, and student and commercial transportation markets under the International and IC brands; and designs, engineers, and produces sheet metal components, including truck cabs and engines.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $21.20 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock decreased 5.05% or $0.0329 during the last trading session, reaching $0.6191. About 623,081 shares traded or 15.41% up from the average. Agile Therapeutics, Inc. (AGRX) has declined 82.95% since June 13, 2017 and is downtrending. It has underperformed by 95.52% the S&P500. Some Historical AGRX News: ; 24/05/2018 – Agile Interoperable Solutions (AIS) Announces Center Point System To Scale And Provide Remote Management For Its Core Integrati; 07/03/2018 – AEye Granted Foundational Patents for Core Solid State MEMS-Based Agile LiDAR and Embedded Al Technology; 07/05/2018 – AGILE GROUP HOLDINGS LTD 3383.HK – APRIL PRE-SALES VALUE RMB8.29 BLN; 12/03/2018 – Agile Therapeutics 4Q Loss/Shr 18c; 21/03/2018 – Agile: 2017 Net Profit CNY6.03 Billion vs. CNY2.28 Billion a Year Ago; 08/03/2018 – SAUDI BANKING SYSTEM IS AGILE TO ADAPT TO CHANGES: TUWAIJRI; 12/03/2018 – Agile Group: 2017 Results Buoyed by Strong Property Sales, Higher Profit Margins; 27/04/2018 – Superion To Showcase Smart, Agile And Unified Finance Solutions At GFOA 2018; 21/03/2018 – Agile 2017 Net Profit CNY6.03 Billion; Above Expectations; 25/03/2018 – Agile Group to Use Net Proceeds for Debt Refinancing

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on July, 27. They expect $-0.17 earnings per share, up 34.62% or $0.09 from last year’s $-0.26 per share. After $-0.21 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -19.05% EPS growth.

Another recent and important Agile Therapeutics, Inc. (NASDAQ:AGRX) news was published by Globenewswire.com which published an article titled: “Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance” on June 07, 2018.

Navistar International Corporation (NYSE:NAV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: